Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management
Authors:
- 4 March 2026
- journal article
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 45 (3) , 101781
Abstract
No abstract availableKeywords
Funding Information
- Université de Caen Normandie
This publication has 9 references indexed in Scilit:
- An Investigation of O-Demethyl Tramadol/Tramadol Ratio for Cytochrome P450 2D6 Phenotyping: The CYTRAM StudyPharmaceutics, 2022
- Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene VariationClinical Pharmacology & Therapeutics, 2021
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid TherapyClinical Pharmacology & Therapeutics, 2021
- Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working GroupClinical and Translational Science, 2019
- Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6Drug Design, Development and Therapy, 2019
- An overview of tramadol and its usage in pain management and future perspectiveBiomedicine & Pharmacotherapy, 2019
- PharmGKB summaryPharmacogenetics and Genomics, 2014
- Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendationsPain, 2012
- The Analgesic Effect of Tramadol After Intravenous Injection in Healthy Volunteers in Relation to CYP2D6Anesthesia & Analgesia, 2006